Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan.
Department of Epidemiology and Biostatistics, School of Public Health, Xuzhou Medical University, Xuzhou 221004, China.
Nutrients. 2021 Feb 11;13(2):590. doi: 10.3390/nu13020590.
Acrylamide, which is present in many daily foods, is a probable human carcinogen. In 2002, it was identified in several common foods. Subsequently, western epidemiologists began to explore the relationship between dietary acrylamide exposure and cancer risk; however, limited suggestive associations were found. This prospective study aimed to examine the association between dietary acrylamide intake and the risk of hematological malignancies, including malignant lymphoma (ML), multiple myeloma (MM), and leukemia. We enrolled 85,303 participants in the Japan Public Health Center-based Prospective study on diet and cancer as from 1995. A food frequency questionnaire that included data on acrylamide in all Japanese foods was used to assess dietary acrylamide intake. We applied multivariable adjusted Cox proportional hazards models to reckon hazard ratios (HRs) for acrylamide intake for both categorical variables (tertiles) and continuous variables. After 16.0 median years of follow-up, 326 confirmed cases of ML, 126 cases of MM, and 224 cases of leukemia were available for final multivariable-adjusted analysis. HRs were 0.87 (95% confidence interval [CI]: 0.64-1.18) for ML, 0.64 (95% CI: 0.38-1.05) for MM, and 1.01 (95% CI: 0.71-1.45) for leukemia. Our results implied that acrylamide may not be related to the risk of hematological malignancies.
丙烯酰胺存在于许多日常食品中，是一种可能的人类致癌物。2002 年，在几种常见食品中发现了丙烯酰胺。随后，西方流行病学家开始探索饮食中丙烯酰胺暴露与癌症风险之间的关系；然而，发现的关联有限。本前瞻性研究旨在检验饮食中丙烯酰胺摄入与血液系统恶性肿瘤（包括恶性淋巴瘤（ML）、多发性骨髓瘤（MM）和白血病）风险之间的关系。我们从 1995 年开始招募了 85303 名参加日本公共卫生中心基于饮食和癌症的前瞻性研究的参与者。使用包含所有日本食品中丙烯酰胺数据的食物频率问卷来评估饮食中丙烯酰胺的摄入量。我们应用多变量调整的 Cox 比例风险模型来计算丙烯酰胺摄入量的风险比（HRs），既用于分类变量（三分位数）也用于连续变量。经过 16.0 年的中位随访，326 例确诊的 ML、126 例 MM 和 224 例白血病病例可用于最终的多变量调整分析。ML 的 HR 为 0.87（95%置信区间 [CI]：0.64-1.18），MM 的 HR 为 0.64（95% CI：0.38-1.05），白血病的 HR 为 1.01（95% CI：0.71-1.45）。我们的结果表明，丙烯酰胺可能与血液系统恶性肿瘤的风险无关。
